IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
UroGen Pharma entered into a strategic partnership with IntraGel Therapeutics, investing up to $7 million to secure an exclusive option to license TumoCure and access IntraGel's SRGel platform. TumoCure is a Phase 2-ready therapy for advanced head and neck cancer that utilizes a biodegradable sustained-release gel to minimize systemic exposure.
Key figures
- Drug Name
- TumoCure
- Deal Value Usd
- 7000000
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.